The incidence of brainstem toxicity following high-dose conformal proton therapy for adult skull-base malignancies

Abstract

Abstract Background

Dose escalation for skull-based malignancies often presents risks to critical adjacent neural structures, including the brainstem. We report the incidence of brainstem toxicity following fractionated high-dose conformal proton therapy and associated dosimetric parameters.

Material and methods

We performed a single-institution review of patients with skull-base chordoma or chondrosarcoma who were treated with proton therapy between February 2007 and January 2020 on a prospective outcomes-tracking protocol. The primary endpoint was grade ≥2 brainstem toxicity. No patients received concurrent chemotherapy, and brainstem toxicity was censored for analysis if it coincided with local disease progression.

Results

We analyzed 163 patients who received a minimum of 45 GyRBE to 0.03 cm³ of the brainstem. Patients were treated to a median total dose of 73.8 (range 64.5–74.4) GyRBE at 1.8 GyRBE per fraction with 17 patients undergoing twice-daily treatment at 1.2 GyRBE per fraction. With a median follow-up of 4 years, the 5-year cumulative incidence of grade ≥2 brainstem injury was 1.3% (95% CI 0.25–4.3%). There was one grade 2, one grade 3, and no grade 4 or 5 events, with all patients recovering function with medical management.

Conclusion

In delivering curative-intent radiotherapy for skull-base chordoma and chondrosarcoma in adults, small volumes of the brainstem can safely receive at least 64 GyRBE with minimal risk of serious brainstem injury.